Navigation Links
Genes May Determine Aspirin's Effect on Advanced Colon Cancer
Date:10/25/2012

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Oct. 24 (HealthDay News) -- For patients suffering from advanced colorectal cancer, aspirin may prolong their lives if their tumor has a certain gene mutation, a new study finds.

"Aspirin appears to work to increase survival of colorectal cancer patients if the tumor has PIK3CA mutation, but does not work if the tumor does not have PIK3CA mutation," said lead researcher Dr. Shuji Ogino, an associate professor in the department of epidemiology at the Harvard School of Public Health.

About 20 percent of colorectal cancers have PIK3CA mutations, according to the study.

"PIK3CA can be potentially tested as a predictive genetic marker for colorectal cancer patients," Ogino said.

"Doctors may be able to make a decision to treat or not to treat with aspirin, based on a PIK3CA test result," he added. "So a PIK3CA test can potentially make a difference to patients."

Ogino cautioned, however, that the findings need to be confirmed.

"An independent validation study is needed before PIK3CA testing can be a part of routine clinical work-up," he said.

For the study, which was published in the Oct. 25 issue of the New England Journal of Medicine, Ogino's team collected data on more than 900 patients with colorectal cancer who were part of the Nurses' Health Study and the Health Professionals Follow-up Study.

The data included their use of aspirin, and whether they had the PIK3CA gene mutation.

The researchers found that 97 percent of the patients with the mutation who were taking aspirin were alive five years after being diagnosed, compared with 74 percent of similar patients who weren't taking aspirin.

Aspirin, however, had no effect on prolonging life among patients who didn't have the PIK3CA gene mutation, the study showed.

Earlier research suggested aspirin could block an enzyme that slows tumor growth in patients with this particular gene mutation, Ogino said, which is why they decided to do the study.

The optimal aspirin dose is unknown, Ogino said. "Baby aspirin may work, but we need more studies about dose," he noted.

Dr. Boris Pasche, director of hematology/oncology at the University of Alabama at Birmingham, said, "While several new drugs have demonstrated efficacy in metastatic colorectal cancer in the past decade, only one of them (oxaliplatin) has proven useful in warding off tumor recurrence in patients with locally advanced disease.

Aspirin has benefits in preventing colorectal cancer, but its role in the treatment of established colorectal cancer is yet to be defined, he said.

"If validated in additional studies, aspirin could become a new drug to be added to the regimen, which is currently the worldwide standard of care for patients with stage III colorectal cancer," Pasche said. "It would significantly improve the outcome of patients with stage III colorectal cancer that carry mutations of the PIK3CA gene."

For Pasche, who wrote an accompanying journal editorial, the bottom line is, "an old drug may become a 21st century targeted therapy ushering [in] a tangible personalized medicine application in colorectal cancer."

Although the researchers found an association between taking aspirin and longer life among colorectal cancer patients, a cause-and-effect relationship was not proven.

More information

For more information on colon cancer, visit the American Cancer Society.

SOURCES: Shuji Ogino, M.D., Ph.D., associate professor, department of epidemiology, Harvard School of Public Health, Boston; Boris Pasche, M.D., Ph.D., professor, medicine, Martha Ann and David L. May Chair in Cancer Research, and director, division of hematology/oncology, the University of Alabama at Birmingham; Oct. 25, 2012, New England Journal of Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genes of Africas Khoe-San Peoples Give Clues to Human Evolution
2. Pinpointing genes that control breast cancer key in finding treatments
3. Discovery of essential genes for drug-resistant bacteria reveals new, high-value drug targets
4. Scientists Spot 5 Genes That Help Shape Faces
5. Study identifies genes associated with genomic expansions that cause disease
6. X-Rays May Up Breast Cancer Risk for Women With Certain Genes: Study
7. Tumor suppressor genes vital to regulating blood precursor cells in fruit flies
8. Binding sites for LIN28 protein found in thousands of human genes
9. Study of tribe could help find East Asian skin color genes
10. Could Your Genes Influence How You Vote?
11. WSU researcher documents links between nutrients, genes and cancer spread
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genes May Determine Aspirin's Effect on Advanced Colon Cancer
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... 24, 2016 , ... Puradigm® & Innovative Solutions today announced ... and processing operations at its production facility, and opened its first two dispensaries ... manufacturer of a complete system of proactive air and surface purification solutions for ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
Breaking Medicine Technology: